Ollin Bio develops novel bispecific antibody therapies for severe ophthalmic diseases like wet AMD and DME. Their lead candidate, OLN324, targets VEGF-A and Angiopoietin-2 to improve anatomic outcomes beyond current anti-VEGF treatments.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
Patients with severe, vision-threatening ophthalmic diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) often experience progressive disease despite current anti-VEGF therapies, necessitating frequent intravitreal injections. Existing treatments can be insufficient, leading to suboptimal anatomic outcomes and continued vision loss.
Solution
Ollin Bio is developing novel therapeutic candidates designed to improve outcomes for patients with severe, vision-threatening ophthalmic conditions. The company's pipeline focuses on advancing treatments that build upon validated biologies while balancing risk and innovation to achieve best-in-disease status. Ollin Bio's approach aims to address unmet needs by targeting a broader spectrum of disease mechanisms. Their lead candidate, OLN324, is a higher potency, small format bispecific antibody targeting both VEGF-A and Angiopoietin-2 (Ang2), which has demonstrated improved anatomic outcomes compared to anti-VEGF therapy alone in preclinical models. Another candidate, OLN102, is a first-in-class bispecific antibody targeting IGF-1R and TSHR, intended for conditions like thyroid eye disease.
Target Audience
Ollin Bio's primary customers are patients suffering from severe, vision-threatening ophthalmic diseases and the healthcare providers who treat them, including ophthalmologists and retinal specialists.
Features
- OLN324: A VEGF-A/Ang2 bispecific antibody designed for enhanced efficacy in wet AMD and DME.
- OLN102: A first-in-class IGF-1R/TSHR bispecific antibody for indications including thyroid eye disease.
- Pipeline development grounded in validated biological pathways with defined regulatory strategies.
- Focus on delivering potential best-in-disease therapies through a combination of risk mitigation and innovation.
- Preclinical and early clinical stage drug candidates targeting significant unmet needs in ophthalmology.